Ferret adrenal gland disease (hyperadrenocorticism): diagnosis and treatment

Bottom line

Ferret adrenocortical disease is a sex-steroid-driven endocrinopathy, not a cortisol-driven Cushing's: chronic gonadotropin (predominantly LH) stimulation of the neutered adrenal cortex drives hyperplasia, adenoma, then adenocarcinoma, with excess estradiol, androstenedione, and 17-hydroxyprogesterone producing the clinical picture [1][5]. Diagnose on signalment and signs (symmetric alopecia, vulvar swelling, pruritus, prostatic/urethral obstruction in males), confirm with a ferret adrenal sex-steroid panel plus abdominal ultrasound, and treat medically with a deslorelin acetate implant (the only FDA-indexed option, ~13–16 months of control per implant) or leuprolide acetate, reserving adrenalectomy for surgical candidates or right-sided/refractory disease [2][3][4][6]. Screen every case for concurrent insulinoma before anesthesia.

Drug facts

Deslorelin acetate implant (Suprelorin F, 4.7 mg)

Class / MOA. Synthetic GnRH superagonist delivered as a slow-release subcutaneous implant. Continuous (rather than pulsatile) GnRH-receptor occupancy downregulates the pituitary gonadotrope, suppressing LH and FSH and thereby removing the trophic stimulus to the abnormal adrenal cortex. It controls signs and lowers plasma sex-steroid concentrations but does not shrink the adrenal tumor and is not curative [1][2].

Approval status. Suprelorin F (4.7 mg deslorelin acetate) is an FDA-indexed product (MIF 900-013, index-listed 2012) specifically indicated for management of adrenal gland cortical disease in the male and female domestic ferret — the one on-label medical option in the U.S. [1]. (The 3-mg formulation used in the original efficacy study and the 4.7-mg/9.4-mg products marketed for chemical castration elsewhere differ by region; confirm what you are dispensing.)

Dose. One 4.7-mg implant SC (typically interscapular) every 12 months per label; re-implant when signs recur [1]. In the pivotal study a single slow-release 3-mg implant eliminated vulvar swelling, pruritus, and sexual behavior within 14 days and gave a mean time to recurrence of 13.7 ± 3.5 months (range 8.5–20.5) [2].

Contraindications / cautions. Pregnancy; an initial "flare" of gonadotropin/sex-steroid release can transiently worsen signs in the first days after implantation. Not a substitute for surgery when a functional adrenal mass needs removal.

Leuprolide acetate (depot)

Class / MOA. GnRH agonist (depot suspension), same pituitary-downregulation mechanism as deslorelin but requiring repeat injection. Off-label in ferrets [3].

Dose. In the original ferret study a single 100 µg IM dose reduced plasma estradiol, 17-hydroxyprogesterone, androstenedione, and DHEA and improved signs, but clinical signs recurred in all ferrets at a mean of 3.7 months (range 1.5–8) [3]. Common clinical dosing uses the monthly depot (roughly 100 µg IM for ferrets <1 kg, 200 µg for >1 kg) or the longer-acting depot every 1–4 months; all such regimens are off-label and derived from the depot's human formulation, so dose from a current formulary and document the off-label discussion [3].

Practical note. Leuprolide's shorter duration and repeat-injection burden have made deslorelin the preferred first-line medical agent where available [6].

Pathophysiology: why neutered ferrets get adrenal disease

Ferret adrenocortical disease is best understood as a gonadotropin-dependent adrenal neoplasm. After gonadectomy, loss of gonadal steroid negative feedback leaves hypothalamic GnRH — and thus pituitary LH and FSH — chronically elevated [1][5]. The ferret adrenal cortex expresses functional LH (and GnRH) receptors, so persistent LH signaling drives progressive adrenocortical enlargement: hyperplasia → adenoma → adenocarcinoma, with the affected cortex secreting adrenal androgens and estrogens rather than cortisol [5]. This is why the syndrome is a sex-steroid excess, not glucocorticoid excess, and why a hypophyseal/gonadotropin blockade (GnRH agonist) is rational therapy.

Early neutering has long been implicated because it lengthens the post-gonadectomy period of unopposed gonadotropin drive; note, however, that current reference sources regard the timing of neutering as less decisive than the fact of neutering itself, and long indoor photoperiods that stimulate GnRH release are a recognized contributor [1]. The clinically actionable point is unchanged: the disease is LH-driven, so suppressing LH controls it.

Clinical signs

Lead sign in most cases is bilaterally symmetric, non-pruritic to pruritic alopecia, typically starting over the tail/flanks and progressing rostrally, in a middle-aged to older ferret (commonly ≥3 years) [6]. Sex-specific and additional signs include:

• Females: vulvar swelling in a spayed jill (a near-pathognomonic sign), sometimes with a mucoid discharge; occasionally mammary changes [1][4].
• Males: return of sexual/aggressive behavior, and — clinically the most urgent — prostatic hyperplasia/cysts causing partial or complete urethral obstruction and stranguria/dysuria. Male urinary obstruction is a surgical/medical emergency and can be the presenting complaint [1].
• Both sexes: pruritus, thin skin, and less commonly muscle wasting, hind-limb weakness, and behavior change [4][5].

Polyuria/polydipsia and the classic pot-bellied cortisol phenotype of canine Cushing's are typically absent — a useful reminder that this is not a cortisol disease.

Diagnosis: sex-steroid panel and ultrasound

Diagnosis is a two-part confirmation on top of signalment and signs:

1. Adrenal sex-steroid panel. Measure estradiol, androstenedione, and 17-hydroxyprogesterone (the University of Tennessee ferret panel is the historical reference assay). Because no single analyte is uniformly elevated, run all three: in the foundational study 96% of affected ferrets had at least one of these elevated but only ~22% had all three high [4]. A raised value in the right clinical context confirms functional adrenal disease; DHEA-S is an additional discriminator [4].
2. Abdominal ultrasound. The most useful imaging tool to localize disease — which gland(s), size, shape, echotexture, and whether the mass involves the right adrenal/caudal vena cava (which changes the surgical plan) [1][6]. Ultrasound also screens for the differentials that mimic the signs: retained ovarian tissue (in a "spayed" jill with vulvar swelling) and prostatic/urinary disease in males. Caveat: diseased glands can be normal in size, so a normal ultrasound does not exclude the disease when signs and steroids fit [4].

Routine pre-treatment minimum database (CBC/chemistry) is important less for adrenal confirmation than to catch comorbidity — above all blood glucose, because concurrent insulinoma is common (see below).

Medical management: deslorelin vs leuprolide

Both agents suppress LH/FSH and reliably improve clinical signs; they differ in duration, route burden, and regulatory status.

	Deslorelin implant (Suprelorin F 4.7 mg)	Leuprolide acetate depot
Regulatory status (US)	FDA-indexed for ferret adrenal disease [1]	Off-label [3]
Route / interval	Single SC implant, re-dose ~q12 months [1]	Repeat IM injection (monthly to q1–4 months depot) [3]
Duration of control	Mean ~13.7 mo to recurrence (range 8.5–20.5) [2]	Mean ~3.7 mo to recurrence (range 1.5–8) [3]
Tumor effect	No tumor shrinkage; not curative [1][2]	No tumor shrinkage; not curative [3]

Deslorelin is the preferred first-line medical option where available: longer control per dose, single implant, and on-label status, with reference sources citing a longer average disease-free interval than leuprolide and even than surgery in some series [6]. Leuprolide remains a reasonable choice when an implant is unavailable or as a bridge. Neither drug addresses an existing functional mass — medical therapy manages the endocrine syndrome; it does not remove the tumor. Counsel owners that signs recur as the implant/injection wanes and re-dosing is expected. For a male presenting with urethral obstruction, medical GnRH-agonist therapy plus prostatic decompression/catheterization stabilizes the patient, but a functional right adrenal mass may still warrant surgery.

Surgical adrenalectomy

Adrenalectomy is the only potentially curative option and is favored for a discrete unilateral (especially left) mass in a good surgical candidate. Left adrenalectomy is relatively straightforward. Right adrenalectomy is substantially harder because the right gland is intimately attached to the caudal vena cava; complete removal may require partial venotomy or vessel-wall dissection, and caval laceration/ligation risks hemorrhage and acute renal injury [6]. Options for right-sided disease include partial adrenalectomy or cytoreduction (cryo/laser) with adjunctive medical therapy. Debulking bilateral disease plus a deslorelin implant is a common combined strategy.

Pre-operative screening is mandatory: check for hypoglycemia (concurrent insulinoma) and stage the abdomen on ultrasound. With appropriate case selection the prognosis for resolution of signs and normal lifespan after adrenalectomy is good to excellent, though contralateral or recurrent disease can develop later [6].

Distinguishing and managing concurrent insulinoma

Insulinoma and adrenal disease are the two most common ferret endocrinopathies and frequently coexist — so evaluate for both, and never anesthetize an adrenal ferret without a blood glucose. They are readily distinguished on presentation and labs:

• Adrenal disease: dermatologic/reproductive signs (alopecia, vulvar swelling, prostatic obstruction), elevated adrenal sex steroids, adrenomegaly on ultrasound; glucose normal [1][4].
• Insulinoma: episodic weakness, ptyalism/nausea, stargazing, collapse or seizures from hypoglycemia (blood glucose typically <60–70 mg/dL) with inappropriately high insulin; pancreatic nodule(s) on ultrasound.

When both are present, correct hypoglycemia peri-operatively and, if operating, address the insulinoma (nodulectomy/partial pancreatectomy) at the same laparotomy as adrenalectomy — but counsel that surgery rarely cures insulinoma and typically slows rather than stops progression [6]. Medical insulinoma management (diet, prednisolone, diazoxide) runs in parallel. See our companion hub on ferret insulinoma management for the hypoglycemia workup and medical protocol, and consider ferret lymphoma among differentials for the older, unwell ferret.

Monitoring

Follow the clinical response, since that is what therapy targets: hair regrowth (usually within ~4 weeks of GnRH-agonist therapy), resolution of vulvar swelling, and relief of prostatic/urinary signs [2][3]. Watch for recurrence of alopecia or behavior/urinary signs as the marker to re-implant deslorelin or re-inject leuprolide [2]. Serial sex-steroid panels can objectively confirm suppression and later relapse but are not required for routine management. Recheck body weight and blood glucose at each visit to catch emerging or concurrent insulinoma. In male obstructive cases, monitor urination closely after starting therapy.

Prognosis

Prognosis is generally favorable for quality of life and is a management rather than a cure story with medical therapy. Deslorelin gives a mean ~13–16 months of control per implant and can be repeated for years; leuprolide gives shorter intervals [2][3][6]. Adrenalectomy of a resectable (especially left) mass can be curative for that gland, with good long-term outcomes, though new or contralateral disease may arise [6]. The main prognostic modifiers are right-adrenal/caval involvement (surgical risk), male urethral obstruction (emergency), and concurrent insulinoma (drives the overall prognosis in many cases).

Frequently Asked Questions

Is ferret adrenal disease the same as Cushing's disease in dogs? No. Canine Cushing's is glucocorticoid (cortisol) excess; ferret adrenocortical disease is driven by excess adrenal sex steroids (estradiol, androstenedione, 17-hydroxyprogesterone) secondary to chronic post-neutering LH stimulation of the adrenal cortex [1][5]. That is why the signs (alopecia, vulvar swelling, prostatic obstruction) and the treatment (GnRH-agonist suppression) differ from canine Cushing's.

What is the recommended deslorelin implant dose for ferret adrenal disease? One 4.7-mg deslorelin acetate (Suprelorin F) implant SC every 12 months, re-implanting when signs recur; it is FDA-indexed for management of adrenal cortical disease in male and female ferrets. It controls signs and lowers sex steroids but does not shrink the tumor and is not curative [1][2].

Deslorelin implant or leuprolide injection — which is better? Deslorelin is generally preferred: a single implant gives a mean ~13.7 months of control versus a mean ~3.7 months for a leuprolide dose, with no repeat-injection burden and on-label status. Leuprolide is off-label and shorter-acting but a reasonable alternative or bridge [2][3][6].

Is leuprolide acetate use in ferrets off-label? Yes. Leuprolide acetate is a human depot GnRH agonist used off-label in ferrets; deslorelin (Suprelorin F) is the only FDA-indexed medical option for this indication [1][3]. Document the off-label discussion and dose from a current formulary.

When should I choose adrenalectomy over medical therapy? Surgery is the only potentially curative option and is favored for a discrete, resectable (especially left) unilateral mass in a good anesthetic candidate. Right adrenal masses are far harder because of caudal vena cava attachment; screen for concurrent insulinoma and stage on ultrasound first [6].

How do I tell adrenal disease apart from insulinoma, and can a ferret have both? Yes — they frequently coexist. Adrenal disease shows dermatologic/reproductive signs with elevated sex steroids and a normal glucose; insulinoma shows hypoglycemia (glucose typically <60–70 mg/dL) with weakness, ptyalism, or seizures. Always check blood glucose in any adrenal ferret before anesthesia [1][4][6].

Which tests confirm ferret adrenal disease? A ferret adrenal sex-steroid panel (estradiol, androstenedione, 17-hydroxyprogesterone) plus abdominal ultrasound to localize the affected gland. Run all three steroids because no single one is uniformly elevated, and remember diseased glands can be normal in size on ultrasound [4].

What is the prognosis? Good for quality of life. Medical therapy is a management (not cure) strategy — deslorelin gives ~13–16 months of control per implant and can be repeated for years; adrenalectomy of a resectable mass can be curative for that gland. Right-caval involvement, male urethral obstruction, and concurrent insulinoma are the main prognostic modifiers [2][6].